|
SG11202111375RA
(en)
|
2019-04-29 |
2021-11-29 |
Univ Pennsylvania |
Novel aav capsids and compositions containing same
|
|
KR20220020261A
(ko)
|
2019-05-03 |
2022-02-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
이염성 백질이영양증의 치료에 유용한 조성물
|
|
CA3162020A1
(en)
|
2019-12-19 |
2021-06-24 |
James M. Wilson |
Compositions for treating friedreich's ataxia
|
|
JP7713956B2
(ja)
|
2020-04-15 |
2025-07-28 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
MX2022014258A
(es)
*
|
2020-05-12 |
2023-02-22 |
Univ Pennsylvania |
Composiciones para la reducción específica de un fármaco de la expresión de transgén.
|
|
TWI900553B
(zh)
|
2020-05-13 |
2025-10-11 |
美商航海家醫療公司 |
Aav蛋白殼之趨性重定向
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
AU2021292200A1
(en)
|
2020-06-17 |
2023-02-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
|
IL299762A
(en)
|
2020-07-13 |
2023-03-01 |
Univ Pennsylvania |
Useful preparations for the treatment of Charcot-Marietot disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
AU2021356684A1
(en)
*
|
2020-10-09 |
2023-05-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
WO2022082109A1
(en)
|
2020-10-18 |
2022-04-21 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
IL303239A
(en)
*
|
2020-12-01 |
2023-07-01 |
Univ Pennsylvania |
Compositions and their uses for the treatment of Engelmann syndrome
|
|
EP4274592A4
(en)
*
|
2021-01-11 |
2025-03-19 |
The Trustees of The University of Pennsylvania |
COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022198079A1
(en)
*
|
2021-03-19 |
2022-09-22 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating propionic acidemia
|
|
EP4323531A1
(en)
|
2021-04-12 |
2024-02-21 |
Affinia Therapeutics Inc. |
Recombinant aav for treatment of neural disease
|
|
WO2023113806A1
(en)
|
2021-12-16 |
2023-06-22 |
Affinia Therapeutics, Inc. |
Recombinant aav for treatment of neural disease
|
|
CA3216004A1
(en)
|
2021-04-23 |
2022-10-27 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
WO2022232267A1
(en)
|
2021-04-27 |
2022-11-03 |
The Trustees Of The University Of Pennsylvania |
Porcine-derived adeno-associated virus capsids and uses thereof
|
|
CN118043468A
(zh)
*
|
2021-06-11 |
2024-05-14 |
分贝治疗公司 |
用于内耳中的细胞类型特异性基因表达的组合物和方法
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4409010A1
(en)
|
2021-10-02 |
2024-08-07 |
The Trustees of The University of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
MX2024004723A
(es)
*
|
2021-10-18 |
2024-07-19 |
Univ Pennsylvania |
Composiciones útiles en el tratamiento del trastorno por deficiencia de cdkl5 (cdd).
|
|
KR20240133693A
(ko)
*
|
2021-11-12 |
2024-09-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
점액다당류증 iiia의 치료를 위한 유전자 요법
|
|
US20250295807A1
(en)
*
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4433169A1
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2023133574A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for treatment of c9orf72-mediated disorders
|
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
CA3249551A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
AAV Capsid Variants and Their Uses
|
|
EP4504797A1
(en)
|
2022-04-06 |
2025-02-12 |
The Trustees of The University of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4532515A1
(en)
|
2022-06-02 |
2025-04-09 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4543473A1
(en)
|
2022-06-22 |
2025-04-30 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
CA3259902A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
AAV Capsid Variants and Their Uses
|
|
US20250388626A1
(en)
|
2022-07-06 |
2025-12-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
EP4551253A1
(en)
*
|
2022-07-08 |
2025-05-14 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes
|
|
JP2025528068A
(ja)
|
2022-08-03 |
2025-08-26 |
ボイジャー セラピューティクス インコーポレイテッド |
血液脳関門を通過させるための組成物及び方法
|
|
KR20250069606A
(ko)
|
2022-09-15 |
2025-05-19 |
보이저 테라퓨틱스, 인크. |
타우 결합 화합물
|
|
EP4594494A2
(en)
*
|
2022-09-26 |
2025-08-06 |
Encoded Therapeutics, Inc. |
Elements for de-targeting gene expression in dorsal root ganglion and/or liver
|
|
EP4634394A2
(en)
|
2022-12-17 |
2025-10-22 |
The Trustees of The University of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
KR20250129743A
(ko)
|
2022-12-29 |
2025-08-29 |
보이저 테라퓨틱스, 인크. |
Mapt를 조절하기 위한 조성물 및 방법
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
AU2024266140A1
(en)
|
2023-05-02 |
2025-09-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
EP4705484A1
(en)
|
2023-05-03 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2024229161A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
TW202444917A
(zh)
|
2023-05-04 |
2024-11-16 |
美商航海家醫療公司 |
Ａａｖ衣殼變異體及其用途
|
|
EP4711461A1
(en)
*
|
2023-05-12 |
2026-03-18 |
Genecombio Ltd. |
Viral vector carrying smn gene expression cassette and use thereof
|
|
TW202516019A
(zh)
|
2023-06-29 |
2025-04-16 |
賓州大學委員會 |
具中樞神經系統靶向模體的突變aav及含有其之組成物
|
|
IL326390A
(en)
|
2023-08-10 |
2026-04-01 |
Univ Pennsylvania |
Compositions and methods for treating spinal muscular atrophy
|
|
WO2025038805A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025122530A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025122644A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025217023A1
(en)
*
|
2024-04-08 |
2025-10-16 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for gangliosidosis type 2 (gm2)
|
|
WO2025235734A2
(en)
|
2024-05-09 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2026010722A1
(en)
|
2024-07-03 |
2026-01-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
WO2026028089A1
(en)
|
2024-07-29 |
2026-02-05 |
Novartis Ag |
Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
|